Literature DB >> 17914915

Polymyxin B: similarities to and differences from colistin (polymyxin E).

Andrea Kwa1, Sofia K Kasiakou, Vincent H Tam, Matthew E Falagas.   

Abstract

Hospital-acquired infections due to multidrug-resistant gram-negative bacteria constitute major health problems, since the medical community is continuously running out of available effective antibiotics and no new agents are in the pipeline. Polymyxins, a group of antibacterials that were discovered during the late 1940s, represent some of the last treatment options for these infections. Only two polymyxins are available commercially, polymyxin E (colistin) and polymyxin B. Although several reviews have been published recently regarding colistin, no review has focused on the similarities and differences between polymyxin B and colistin. These two medications have many similarities with respect to mechanism of action, antimicrobial spectrum, clinical uses and toxicity. However, they also differ in several aspects, including chemical structure, formulation, potency, dosage and pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914915     DOI: 10.1586/14787210.5.5.811

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  39 in total

1.  Inactivation of Polymyxin by Hydrolytic Mechanism.

Authors:  Jianhua Yin; Gang Wang; Dan Cheng; Jianv Fu; Juanping Qiu; Zhiliang Yu
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.

Authors:  Seema Patel; Shadab Ahmed; J Satya Eswari
Journal:  World J Microbiol Biotechnol       Date:  2015-06-04       Impact factor: 3.312

3.  Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.

Authors:  Andrea L H Kwa; Kamilia Abdelraouf; Jenny G H Low; Vincent H Tam
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

4.  In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Authors:  Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

5.  Thermodynamics of RTA3 peptide binding to membranes and consequences for antimicrobial activity.

Authors:  Ayman Hawrani; Robin A Howe; Timothy R Walsh; Christopher E Dempsey
Journal:  Biochim Biophys Acta       Date:  2010-03-24

Review 6.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

7.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

Authors:  K L Seib; D Serruto; F Oriente; I Delany; J Adu-Bobie; D Veggi; B Aricò; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

10.  Disruption of Membrane by Colistin Kills Uropathogenic Escherichia coli Persisters and Enhances Killing of Other Antibiotics.

Authors:  Peng Cui; Hongxia Niu; Wanliang Shi; Shuo Zhang; Hao Zhang; Joseph Margolick; Wenhong Zhang; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.